Burns is an indication for drug development with over 50 pipeline drugs currently active. According to GlobalData, preregistered drugs for Burns have a 100% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Burns compared to historical benchmarks. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Likelihood of Approval Analysis for Burns

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Burns overview

Burns result from tissue damage caused by heat, chemicals, electricity, or radiation, with severity ranging from mild to life-threatening. Classification into first, second, or third-degree burns depends on the depth and extent of tissue involvement. Immediate treatment aims to stop the burning process, cool the affected area, and prevent infection. Severe burns may require hospitalization, including fluid resuscitation, wound debridement, and skin grafting. Complications such as infection, scarring, and long-term physical or psychological effects are common. Prevention through safety measures like smoke detectors, fire extinguishers, and proper handling of hot objects is crucial in reducing the incidence of burns.

For a complete picture of PTSR and LoA scores for drugs in Burns, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article. 

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.